| Expression pattern: |
UP |
| Associated gene: |
AGO2, IGF1R, AKT |
| Associated microRNA: |
miR-377-3p, miR-494-3p |
| Biological function: |
promotes SCLC progression by increasing cell viability and colony formation, accelerating cell cycle progression, inhibiting apoptosis, and promoting tumor growth in vivo |
| Molecular mechanism: |
ceRNA/miRNA sponge mechanism: circVAPA sponges miR-377-3p and miR-494-3p to relieve repression of IGF1R, thereby activating AKT signaling |
| Biological pathway or process: |
PI3K/AKT (promotes); proliferation (promotes); apoptosis (inhibits); cell cycle (promotes); ceRNA regulation (promotes); drug resistance (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; Microarray; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry) |
| Clinical significance: |
circVAPA is upregulated in SCLC tissues and serum and is proposed as a promising biomarker and therapeutic target; combination of circVAPA inhibition with BMS-536924 may improve treatment |
| Description: |
circVAPA (hsa_circ_0006990), derived from VAPA, is upregulated in SCLC tissues, serum, and SCLC cell lines. It mainly localizes to the cytoplasm and promotes SCLC proliferation/viability and tumor growth by sponging miR-377-3p and miR-494-3p to increase IGF1R and activate the PI3K/AKT signaling axis, and its depletion enhances response to the IGF1R inhibitor BMS-536924. |
| Confidence score: |
0.8737 |